An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001565:Benzoates / Q000627:therapeutic use* / Q000633:toxicity; D001772:Blood Cell Count; D002277:Carcinoma / Q000188:drug therapy*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011344:Procarbazine / Q000627:therapeutic use / Q000633:toxicity; D013997:Time Factors
D000970:Antineoplastic Agents; D001565:Benzoates; D011344:Procarbazine; D005472:Fluorouracil